^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:Gastric Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor) +
    oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Preferred Regimens...HER2 overexpression negative...Fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

    Excerpt:
    ...Is confirmed by histopathology and/or cytology her2-negative or HER2 status unknown late recurrence or stomach esophagus stomach/integration of adenocarcinoma; 4....
    Trial ID:
    FISSION
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

    Excerpt:
    ...Negative Her2; 9....
    Trial ID:
    NCT06094868
    More C2 evidence